Drug Trial Radar · NCT00276640
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
Last checked: Nov 19, 2026Latest source record: Apr 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,417
Actual
Start
Apr 1, 2004
Primary completion
Dec 31, 2015
Study completion May 31, 2017
Sponsor
- Lead sponsor
- Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.
Conditions
- Primary Central Nervous System Neoplasms
Interventions
vincristine, carboplatinDrug
vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
vincristine, carboplatin, etoposideDrug
vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21 carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21 etoposide: 100 mg/m² i.v., week 1,4,7,10
radiation therapyRadiation
intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: week 24, and at 1, 3, and 5 years
- Event-free survivalTime frame: week 24 and at 1, 3, and 5 years
- Overall survivalTime frame: week 24 and at 1, 3, and 5 years
Locations
13 sites in 12 countries. Site status is shown where the registry gives one.
Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik
Vienna, Austria
Universitair Ziekenhuis Gent
Ghent, Belgium
Children's Hospital Zagreb
Zagreb, Croatia
Aalborg Hospital
Aalborg, Denmark
Institut Gustave Roussy
Villejuif, France
Klinikum Augsburg
Augsburg, Germany
Azienda Ospedaliera di Padova
Padova, Italy
University of Tromso
Tromsø, Norway
Children's Memorial Health Institute
Warsaw, Poland
Hospital San Joao
Porto, Portugal
University Children's Hospital
Zurich, Switzerland
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom
Queen's Medical Centre
Nottingham, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.